Empagliflozin decreased cardiovascular death or heart failure hospitalisation risk across the range of baseline health status. Empagliflozin improved health status across various domains, and this benefit was sustained during long-term follow-up.
Type of Study
Complementary analysis - aimed to evaluate whether the benefits of empagliflozin varied by baseline health status assessed by the Kansas City Cardiomyopathy Questionnaires-clinical summary score and how empagliflozin impacted patient-reported outcomes - of the EMPEROR-Reduced trial, a randomised, double-blind, placebo-controlled, trial that enrolled 3730 patients whith chronic HF and a left ventricular ejection fraction ≤40%.
Importance for clinical practice
Patiens with HEFrEF should be treated with medications for improving outcome but also for improving the quality of life : empagliflozin showed benefits in both endpoints.